Cargando…

Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys

An immune response for a nasal ovalbumin (OVA) powder formulation with an applied nasal delivery platform technology, consisting of a powdery nasal carrier and a device, was evaluated in monkeys with similar upper respiratory tracts and immune systems to those of humans, in order to assess the appli...

Descripción completa

Detalles Bibliográficos
Autores principales: Torikai, Yusuke, Sasaki, Yuji, Sasaki, Keita, Kyuno, Akifumi, Haruta, Shunji, Tanimoto, Akihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Pharmacists Association®. Published by Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836740/
https://www.ncbi.nlm.nih.gov/pubmed/33278410
http://dx.doi.org/10.1016/j.xphs.2020.11.023
_version_ 1783642811532312576
author Torikai, Yusuke
Sasaki, Yuji
Sasaki, Keita
Kyuno, Akifumi
Haruta, Shunji
Tanimoto, Akihide
author_facet Torikai, Yusuke
Sasaki, Yuji
Sasaki, Keita
Kyuno, Akifumi
Haruta, Shunji
Tanimoto, Akihide
author_sort Torikai, Yusuke
collection PubMed
description An immune response for a nasal ovalbumin (OVA) powder formulation with an applied nasal delivery platform technology, consisting of a powdery nasal carrier and a device, was evaluated in monkeys with similar upper respiratory tracts and immune systems to those of humans, in order to assess the applicability to a vaccine antigen. Nasal distribution and retention studies using a 3D nasal cavity model and manganese-enhanced MRI were conducted by administering nasal dye and manganese powder formulations with the applied technology. Systemic and mucosal immune responses for the nasal OVA powder formulation were evaluated by determining serum IgG and nasal wash IgA antibody titers. The nasal dye and manganese powder formulations showed wider distribution and longer retention time than did a nasal liquid formulation. The nasal OVA powder formulation also showed comparable and higher antigen-specific IgG antibody titer to an injection and nasal liquid formulation, respectively. Furthermore, antigen-specific IgA antibody response was detected only for the nasal OVA powder formulation. The present study suggests that the technology, originally designed for drug absorption, is promising for nasal vaccines, enabling both a mucosal immunity response as the first line of defense and systemic immunity response as a second line of defense against infection.
format Online
Article
Text
id pubmed-7836740
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Pharmacists Association®. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78367402021-01-26 Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys Torikai, Yusuke Sasaki, Yuji Sasaki, Keita Kyuno, Akifumi Haruta, Shunji Tanimoto, Akihide J Pharm Sci Pharmaceutics, Drug Delivery and Pharmaceutical Technology An immune response for a nasal ovalbumin (OVA) powder formulation with an applied nasal delivery platform technology, consisting of a powdery nasal carrier and a device, was evaluated in monkeys with similar upper respiratory tracts and immune systems to those of humans, in order to assess the applicability to a vaccine antigen. Nasal distribution and retention studies using a 3D nasal cavity model and manganese-enhanced MRI were conducted by administering nasal dye and manganese powder formulations with the applied technology. Systemic and mucosal immune responses for the nasal OVA powder formulation were evaluated by determining serum IgG and nasal wash IgA antibody titers. The nasal dye and manganese powder formulations showed wider distribution and longer retention time than did a nasal liquid formulation. The nasal OVA powder formulation also showed comparable and higher antigen-specific IgG antibody titer to an injection and nasal liquid formulation, respectively. Furthermore, antigen-specific IgA antibody response was detected only for the nasal OVA powder formulation. The present study suggests that the technology, originally designed for drug absorption, is promising for nasal vaccines, enabling both a mucosal immunity response as the first line of defense and systemic immunity response as a second line of defense against infection. American Pharmacists Association®. Published by Elsevier Inc. 2020-12-03 /pmc/articles/PMC7836740/ /pubmed/33278410 http://dx.doi.org/10.1016/j.xphs.2020.11.023 Text en © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Pharmaceutics, Drug Delivery and Pharmaceutical Technology
Torikai, Yusuke
Sasaki, Yuji
Sasaki, Keita
Kyuno, Akifumi
Haruta, Shunji
Tanimoto, Akihide
Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title_full Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title_fullStr Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title_full_unstemmed Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title_short Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys
title_sort evaluation of systemic and mucosal immune responses induced by a nasal powder delivery system in conjunction with an ova antigen in cynomolgus monkeys
topic Pharmaceutics, Drug Delivery and Pharmaceutical Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836740/
https://www.ncbi.nlm.nih.gov/pubmed/33278410
http://dx.doi.org/10.1016/j.xphs.2020.11.023
work_keys_str_mv AT torikaiyusuke evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys
AT sasakiyuji evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys
AT sasakikeita evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys
AT kyunoakifumi evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys
AT harutashunji evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys
AT tanimotoakihide evaluationofsystemicandmucosalimmuneresponsesinducedbyanasalpowderdeliverysysteminconjunctionwithanovaantigenincynomolgusmonkeys